InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $16.270 0.67 (3.96%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,522 Appendix 4E and 2025 Annual Report 20 Feb 2026 8:52AM $9.130 $16.270 risen by 78.20%
$5,522 Change in substantial holding 20 Feb 2026 8:18AM $9.130 $16.270 risen by 78.20%
$5,522 Telix Submits EU MAA for TLX101-Px Brain Cancer Imaging 18 Feb 2026 8:16AM $8.840 $16.270 risen by 84.05%
$5,522 Change in substantial holding 9 Feb 2026 8:11AM $9.850 $16.270 risen by 65.18%
$5,522 App 3Z Final Director Interests - T Olson 4 Feb 2026 8:27AM $10.210 $16.270 risen by 59.35%
$5,522 Telix Full Year Results 2025 Investor Webcast Notification 4 Feb 2026 8:27AM $10.210 $16.270 risen by 59.35%
$5,522 Chair Resignation, Dr Mark Nelson appointed Interim Chair 3 Feb 2026 9:07AM $10.480 $16.270 risen by 55.25%
$5,522 Change in substantial holding 2 Feb 2026 8:20PM $10.480 $16.270 risen by 55.25%
$5,522 Becoming a substantial holder 27 Jan 2026 8:11AM $10.950 $16.270 risen by 48.58%
$5,522 Ceasing to be a substantial holder from CGF 23 Jan 2026 4:08PM $10.950 $16.270 risen by 48.58%
$5,522 Pending Release of Shares from Voluntary Escrow 23 Jan 2026 8:25AM $10.920 $16.270 risen by 48.99%
$5,522 Ceasing to be a substantial holder 23 Jan 2026 8:24AM $10.920 $16.270 risen by 48.99%
$5,522 Telix Achieves FY25 Guidance - US$804M, Q4 Growth 20 Jan 2026 5:07PM $11.490 $16.270 risen by 41.60%
$5,522 Chinese NMPA Accepts New Drug Application for Illuccix 20 Jan 2026 8:25AM $11.280 $16.270 risen by 44.24%
$5,522 Appendix 2A updated 14 Jan 2026 8:35AM $11.000 $16.270 risen by 47.91%
$5,522 Notification of cessation of securities - TLX 13 Jan 2026 8:23AM $11.200 $16.270 risen by 45.27%
$5,522 Telix JP Morgan Healthcare Conference 2026 Presentation 12 Jan 2026 5:52PM $11.200 $16.270 risen by 45.27%
$5,522 Notification regarding unquoted securities - TLX 24 Dec 2025 8:24AM $11.940 $16.270 risen by 36.26%
$5,522 Application for quotation of securities - TLX 24 Dec 2025 8:24AM $11.940 $16.270 risen by 36.26%
$5,522 Precision Medicine Portfolio Update 22 Dec 2025 8:31AM $11.830 $16.270 risen by 37.53%
$5,522 ProstACT Global Study Status 17 Dec 2025 7:17PM $11.730 $16.270 risen by 38.70%
$5,522 Securities Dealing Policy - Updated 15 Dec 2025 8:29AM $13.740 $16.270 risen by 18.41%
$5,522 1st Patient Dosed in ProstACT Global Randomized Tx Expansion 8 Dec 2025 8:32AM $14.810 $16.270 risen by 9.86%
$5,522 Becoming a substantial holder 17 Nov 2025 8:17AM $14.130 $16.270 risen by 15.15%
$5,522 Appendix 3Y Change in Director Interests - C Behrenbruch 7 Nov 2025 8:25AM $15.160 $16.270 risen by 7.32%

76 - 100 of 945 results

Page 4 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.